BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 33891712)

  • 1. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P; Tchounguen J; Pettigrew C; Lim C; Lin Z; Lu H; Moghekar A; Albert M; Soldan A;
    J Alzheimers Dis; 2023; 92(1):323-339. PubMed ID: 36744337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
    Eloyan A; Thangarajah M; An N; Borowski BJ; Reddy AL; Aisen P; Dage JL; Foroud T; Ghetti B; Griffin P; Hammers D; Iaccarino L; Jack CR; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Nudelman K; Rumbaugh M; Soleimani-Meigooni DN; Toga A; Touroutoglou A; Atri A; Day GS; Duara R; Graff-Radford NR; Honig LS; Jones DT; Masdeu J; Mendez MF; Musiek E; Onyike CU; Rogalski E; Salloway S; Sha S; Turner RS; Wingo TS; Wolk DA; Womack K; Beckett L; Gao S; Carrillo MC; Rabinovici G; Apostolova LG; Dickerson B; Vemuri P;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S89-S97. PubMed ID: 37491599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD.
    Kamal F; Morrison C; Maranzano J; Zeighami Y; Dadar M
    Geroscience; 2023 Feb; 45(1):1-16. PubMed ID: 36229760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. White matter hyperintensities and their relationship to cognition: Effects of segmentation algorithm.
    Tubi MA; Feingold FW; Kothapalli D; Hare ET; King KS; Thompson PM; Braskie MN;
    Neuroimage; 2020 Feb; 206():116327. PubMed ID: 31682983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a Relation Between Hippocampal Volume, White Matter Hyperintensities, and Cognition in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Caillaud M; Hudon C; Boller B; Brambati S; Duchesne S; Lorrain D; Gagnon JF; Maltezos S; Mellah S; Phillips N; ; Belleville S
    J Gerontol B Psychol Sci Soc Sci; 2020 Aug; 75(7):1382-1392. PubMed ID: 31758692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between white matter hyperintensity load and grey matter atrophy in mild cognitive impairment is not unidirectional.
    Vipin A; Wong BYX; Kumar D; Low A; Ng KP; Kandiah N
    Aging (Albany NY); 2021 Apr; 13(8):10973-10988. PubMed ID: 33861727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Asymmetrical White Matter Hyperintensities and Apolipoprotein E4 on Cognitive Impairment.
    Low A; Ng KP; Chander RJ; Wong B; Kandiah N
    J Alzheimers Dis; 2019; 70(3):953-964. PubMed ID: 31306121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.
    Chan CK; Pettigrew C; Soldan A; Zhu Y; Wang MC; Albert M; Rosenberg PB;
    J Alzheimers Dis; 2022; 86(3):1415-1426. PubMed ID: 35213370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between brain amyloid deposition and longitudinal changes of white matter hyperintensities.
    Cha WJ; Yi D; Ahn H; Byun MS; Chang YY; Choi JM; Kim K; Choi H; Jung G; Kang KM; Sohn CH; Lee YS; Kim YK; Lee DY
    Alzheimers Res Ther; 2024 Mar; 16(1):50. PubMed ID: 38454444
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Mirza SS; Saeed U; Knight J; Ramirez J; Stuss DT; Keith J; Nestor SM; Yu D; Swardfager W; Rogaeva E; St George Hyslop P; Black SE; Masellis M;
    Neurology; 2019 Nov; 93(19):e1807-e1819. PubMed ID: 31575706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: a cross-sectional study.
    Bernal J; Schreiber S; Menze I; Ostendorf A; Pfister M; Geisendörfer J; Nemali A; Maass A; Yakupov R; Peters O; Preis L; Schneider L; Herrera AL; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Rostamzadeh A; Glanz W; Buerger K; Janowitz D; Ewers M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Laske C; Munk MH; Spottke A; Roy N; Dobisch L; Dechent P; Scheffler K; Hetzer S; Wolfsgruber S; Kleineidam L; Schmid M; Berger M; Jessen F; Wirth M; Düzel E; Ziegler G
    Alzheimers Res Ther; 2023 May; 15(1):97. PubMed ID: 37226207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
    Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
    Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
    Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White matter hyperintensity patterns: associations with comorbidities, amyloid, and cognition.
    Bachmann D; von Rickenbach B; Buchmann A; Hüllner M; Zuber I; Studer S; Saake A; Rauen K; Gruber E; Nitsch RM; Hock C; Treyer V; Gietl A
    Alzheimers Res Ther; 2024 Apr; 16(1):67. PubMed ID: 38561806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.